InnoCare’s TYK2 Inhibitor Soficitinib Hits Phase III Goal in Atopic Dermatitis

InnoCare Pharma Ltd. ( (HK:9969) ) has shared an announcement.

InnoCare Pharma announced that its Phase III registrational trial of soficitinib, an internally developed next-generation oral TYK2 inhibitor, in adults with moderate-to-severe atopic dermatitis met its primary endpoint with statistically significant and clinically meaningful improvement. Multiple secondary endpoints were also achieved, and the safety profile remained consistent with earlier studies, with no new safety signals observed.

The company plans to complete long-term safety follow-up in the ongoing Phase III study and move ahead with regulatory filings for soficitinib in atopic dermatitis, positioning the drug as a potential well-tolerated oral option in a market that still lacks sufficient sustained-disease-control therapies. Soficitinib is simultaneously being evaluated in four other autoimmune indications, underscoring InnoCare’s broader strategy to build a franchise in autoimmune and inflammatory disease treatments.

The most recent analyst rating on (HK:9969) stock is a Buy
with a HK$17.00 price target.
To see the full list of analyst forecasts on InnoCare Pharma Ltd. stock,
see the HK:9969 Stock Forecast page.